Company intelligence / Profile preview

Axiom Bio

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Axiom Bio has released and validated an AI-powered liver toxicity platform that reportedly matches or surpasses conventional animal/cell models in predictive accuracy. Early results (presented at SOT 2025) show 70–75% sensitivity and ~90% specificity for clinical liver injury, with validation including predictions for programs such as lotiglipron, danuglipron, and orforglipron. Pilots with multiple major pharma are ongoing.

Therapeutic areas: GastroenterologyOther
Modalities: Small moleculeMacrocycleMolecular gluePROTACs
Industry: Drug Discovery Services

Partnerships

Six of the top twenty global pharmaceutical companies (not individually named)Major agrochemical companyMultiple hedge funds and biotechnology firms

Beyond the preview

Go deeper on Axiom Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axiom Bio.

Explore the full profile